| Name | Title | Contact Details |
|---|
Pharmaceutical Education and Research Institute Inc is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novocardia is on a mission to transform how cardiovascular disease care is delivered in the United States, and aims to help patients with heart and vascular disease live longer, healthier, and more satisfying lives. We are committed to putting cardiologists, and their patients, at the center of care by investing in our partner practices, deploying purpose-built data and analytics tools to improve patient outcomes, and enabling our partners to transition more successfully to value-based care.
Avantec Software is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avanti Hospitals currently owns and operates four acute care hospitals: East Los Angeles Doctors Hospital, Memorial Hospital of Gardena, Community Hospital of Huntington Park, and Coast Plaza Hospital, all located near Los Angeles, California. Our mission is to provide affordable, high quality healthcare services to our community with consistency and compassion. Avanti is committed to cooperating with and supporting the long-term needs and objectives of each community we serve. We understand the impact we have on our communities and the potential to improve overall health. We have worked hard to establish a reputation of quality and trust in our communities, including local physicians and governments. At each of our hospitals, we seek to implement community support through a variety of initiatives that are specific to each individual community. With nearly 2,000 employees and over 775 physicians, the Avanti team is committed to delivering the highest quality care to our patients through a broad range of medical services. We also continue to add new programs and technology to meet the meet the growing needs of the communities we serve.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.